Matches in SemOpenAlex for { <https://semopenalex.org/work/W2180996939> ?p ?o ?g. }
- W2180996939 endingPage "1213" @default.
- W2180996939 startingPage "1207" @default.
- W2180996939 abstract "This study analyzed the anti-myeloma effect of zoledronic acid monotherapy by investigating patients at the time of asymptomatic biochemical relapse. One hundred patients were randomized to receive either zoledronic acid (4 mg iv/4 weeks, 12 doses) (n=51) or not (n=49). Experimental and control groups were well balanced for disease and prognostic features. Zoledronic acid did not show an antitumor effect according to changes in M-component. However, there were fewer symptomatic progressions in the experimental group than in the control group (34 versus 41, respectively; P=0.05) resulting in a median time to symptoms of 16 versus 10 months (P=0.161). The median time to next therapy was also slightly longer for the treated group than the untreated, control group (13.4 versus 10.1 months), although the difference was not statistically significant (P=0.360). The pattern of relapses was different for treated versus control patients: progressive bone disease (8 versus 20), anemia (24 versus 18), renal dysfunction (1 versus 2), and plasmacytomas (1 versus 1, respectively). This concurred with fewer skeletal-related events in the treated group than in the control group (2 versus 14), with a projected 4-year event proportion of 6% versus 40% (P<0.001). In summary, zoledronic acid monotherapy does not show an antitumor effect on biochemical relapses in multiple myeloma, but does reduce the risk of progression with symptomatic bone disease and skeletal complications. This trial was registered in the ClinicalTrials.gov database with code NCT01087008." @default.
- W2180996939 created "2016-06-24" @default.
- W2180996939 creator A5000193525 @default.
- W2180996939 creator A5013916379 @default.
- W2180996939 creator A5020989412 @default.
- W2180996939 creator A5021328479 @default.
- W2180996939 creator A5029958963 @default.
- W2180996939 creator A5035515070 @default.
- W2180996939 creator A5035866456 @default.
- W2180996939 creator A5051903959 @default.
- W2180996939 creator A5054952877 @default.
- W2180996939 creator A5059482051 @default.
- W2180996939 creator A5064147442 @default.
- W2180996939 creator A5068695589 @default.
- W2180996939 creator A5071261900 @default.
- W2180996939 creator A5073739479 @default.
- W2180996939 creator A5081688805 @default.
- W2180996939 creator A5083734088 @default.
- W2180996939 creator A5084354003 @default.
- W2180996939 creator A5088242526 @default.
- W2180996939 date "2015-06-11" @default.
- W2180996939 modified "2023-10-18" @default.
- W2180996939 title "Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial" @default.
- W2180996939 cites W1539177534 @default.
- W2180996939 cites W1906448835 @default.
- W2180996939 cites W1932993947 @default.
- W2180996939 cites W1972062342 @default.
- W2180996939 cites W1983807890 @default.
- W2180996939 cites W1991473434 @default.
- W2180996939 cites W2003734726 @default.
- W2180996939 cites W2011926580 @default.
- W2180996939 cites W2031650256 @default.
- W2180996939 cites W2032640560 @default.
- W2180996939 cites W2033294313 @default.
- W2180996939 cites W2034663338 @default.
- W2180996939 cites W2044436186 @default.
- W2180996939 cites W2047727360 @default.
- W2180996939 cites W2082853777 @default.
- W2180996939 cites W2090669976 @default.
- W2180996939 cites W2091552137 @default.
- W2180996939 cites W2100738529 @default.
- W2180996939 cites W2103011422 @default.
- W2180996939 cites W2103289287 @default.
- W2180996939 cites W2118793293 @default.
- W2180996939 cites W2119486128 @default.
- W2180996939 cites W2120400738 @default.
- W2180996939 cites W2135892640 @default.
- W2180996939 cites W2140741067 @default.
- W2180996939 cites W2148154473 @default.
- W2180996939 cites W2159771593 @default.
- W2180996939 cites W2170515647 @default.
- W2180996939 cites W2276350038 @default.
- W2180996939 cites W2325302070 @default.
- W2180996939 cites W244262072 @default.
- W2180996939 cites W4243790874 @default.
- W2180996939 cites W4256054641 @default.
- W2180996939 cites W60551495 @default.
- W2180996939 doi "https://doi.org/10.3324/haematol.2015.128439" @default.
- W2180996939 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4800701" @default.
- W2180996939 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26069291" @default.
- W2180996939 hasPublicationYear "2015" @default.
- W2180996939 type Work @default.
- W2180996939 sameAs 2180996939 @default.
- W2180996939 citedByCount "19" @default.
- W2180996939 countsByYear W21809969392016 @default.
- W2180996939 countsByYear W21809969392017 @default.
- W2180996939 countsByYear W21809969392018 @default.
- W2180996939 countsByYear W21809969392019 @default.
- W2180996939 countsByYear W21809969392020 @default.
- W2180996939 countsByYear W21809969392021 @default.
- W2180996939 countsByYear W21809969392022 @default.
- W2180996939 countsByYear W21809969392023 @default.
- W2180996939 crossrefType "journal-article" @default.
- W2180996939 hasAuthorship W2180996939A5000193525 @default.
- W2180996939 hasAuthorship W2180996939A5013916379 @default.
- W2180996939 hasAuthorship W2180996939A5020989412 @default.
- W2180996939 hasAuthorship W2180996939A5021328479 @default.
- W2180996939 hasAuthorship W2180996939A5029958963 @default.
- W2180996939 hasAuthorship W2180996939A5035515070 @default.
- W2180996939 hasAuthorship W2180996939A5035866456 @default.
- W2180996939 hasAuthorship W2180996939A5051903959 @default.
- W2180996939 hasAuthorship W2180996939A5054952877 @default.
- W2180996939 hasAuthorship W2180996939A5059482051 @default.
- W2180996939 hasAuthorship W2180996939A5064147442 @default.
- W2180996939 hasAuthorship W2180996939A5068695589 @default.
- W2180996939 hasAuthorship W2180996939A5071261900 @default.
- W2180996939 hasAuthorship W2180996939A5073739479 @default.
- W2180996939 hasAuthorship W2180996939A5081688805 @default.
- W2180996939 hasAuthorship W2180996939A5083734088 @default.
- W2180996939 hasAuthorship W2180996939A5084354003 @default.
- W2180996939 hasAuthorship W2180996939A5088242526 @default.
- W2180996939 hasBestOaLocation W21809969391 @default.
- W2180996939 hasConcept C126322002 @default.
- W2180996939 hasConcept C141071460 @default.
- W2180996939 hasConcept C168563851 @default.
- W2180996939 hasConcept C2776326535 @default.
- W2180996939 hasConcept C2776364478 @default.
- W2180996939 hasConcept C2777910003 @default.